These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 15890569)

  • 21. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
    Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
    Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
    Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
    Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Akt expression may predict favorable prognosis in cholangiocarcinoma.
    Javle MM; Yu J; Khoury T; Chadha KS; Iyer RV; Foster J; Kuvshinoff BW; Gibbs JF; Geradts J; Black JD; Brattain MG
    J Gastroenterol Hepatol; 2006 Nov; 21(11):1744-51. PubMed ID: 16984600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.
    Shipley WU; Kaufman DS; Heney NM; Althausen AF; Zietman AL
    J Urol; 1999 Aug; 162(2):445-50; discussion 450-1. PubMed ID: 10411054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
    Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
    Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
    Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
    Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.
    Yamashita H; Murakami N; Asari T; Okuma K; Ohtomo K; Nakagawa K
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1165-72. PubMed ID: 19101092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancer.
    Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Inoue Y; Noguchi H; Honda N
    Oncol Rep; 2007 Jul; 18(1):3-7. PubMed ID: 17549338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
    Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
    Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery.
    Galizia G; Lieto E; Ferraraccio F; De Vita F; Castellano P; Orditura M; Imperatore V; La Mura A; La Manna G; Pinto M; Catalano G; Pignatelli C; Ciardiello F
    Ann Surg Oncol; 2006 Jun; 13(6):823-35. PubMed ID: 16614884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
    Goff BA; Ries JA; Els LP; Coltrera MD; Gown AM
    Gynecol Oncol; 1998 Sep; 70(3):378-85. PubMed ID: 9790791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
    DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
    J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor as a predictor of tumor response to preoperative chemoradiation in locally advanced gastric carcinoma.
    Sirak I; Petera J; Hatlova J; Vosmik M; Melichar B; Dvorak J; Zoul Z; Tycova V; Lesko M; Hajduch M
    Strahlenther Onkol; 2008 Nov; 184(11):592-7. PubMed ID: 19016018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer.
    Lee SE; Chow NH; Chi YC; Tzai TS; Yang WH; Lin SN
    Anticancer Res; 1994; 14(3B):1317-24. PubMed ID: 7915094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
    Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
    Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.
    Gorgoulis VG; Barbatis C; Poulias I; Karameris AM
    Mod Pathol; 1995 Sep; 8(7):758-64. PubMed ID: 8539234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
    Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group.
    Bonin SR; Pajak TF; Russell AH; Coia LR; Paris KJ; Flam MS; Sauter ER
    Cancer; 1999 Mar; 85(6):1226-33. PubMed ID: 10189126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group.
    Chakravarti A; Seiferheld W; Tu X; Wang H; Zhang HZ; Ang KK; Hammond E; Curran W; Mehta M
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):318-27. PubMed ID: 15890570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.